In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms.
In vitro activity of ramoplanin, a cyclic lipoglycopeptide, against 92 vancomycin-resistant gram-positive organisms was evaluated. Ramoplanin demonstrated potent activity against many highly vancomycin-resistant organisms including enterococci (MICs for 90% of strains tested of 0.5 micrograms/ml) and against Lactobacillus spp., Leuconostoc spp., and Pediococcus spp., all of which were inhibited at concentrations of < or = 0.25 micrograms/ml. This drug or a derivative compound merits further investigation as a potential therapeutic agent for infections due to vancomycin-resistant enterococci.
Collins
L A
LA
Department of Medicine, New England Deaconess Hospital, Boston, Massachusetts 02215.
Eliopoulos
G M
GM
Wennersten
C B
CB
Ferraro
M J
MJ
Moellering
R C
RC
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D047630:Depsipeptides; D004352:Drug Resistance, Microbial; D016983:Enterococcus / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D007700:Kinetics; D008826:Microbial Sensitivity Tests; D010456:Peptides, Cyclic; D014640:Vancomycin / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D047630:Depsipeptides; D010456:Peptides, Cyclic; C041438:ramoplanin; D014640:Vancomycin